Skip to main content
Fig. 2 | BMC Surgery

Fig. 2

From: Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis

Fig. 2

Comparisons of recurrence-free (RFS), cancer-specific (CSS), unresectable recurrence-free (URRFS), remnant liver recurrence-free (RLRFS), and extrahepatic recurrence-free (EHRFS) survival in the entire cohort. The L-OHP (+) and (−) groups had no significant differences in RFS (hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.48–1.32, p = 0.38), CSS (HR 1.16, 95% CI 0.63–2.16, p = 0.63), URRFS (HR 1.09, 95% CI 0.63–1.89, p = 0.77), RLRFS (HR 0.77, 95% CI 0.43–1.35, p = 0.36), and EHRFS (HR 0.98, 95% CI 0.55–1.76, p = 0.96)

Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us